Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Market Dynamics
- Emerging Trends
- Analysis by Segment
- Regional Analysis
- Conclusion
Chapter 2 Market Overview
- Overview
- Macroeconomic Factor Analysis
- Impact of U.S. Tariff Policies on the 3D Printing Drugs Market
- Impact of Rising R&D Costs and Return on Investment Pressures on the 3D Printing Drugs Market
- Impact of Ongoing Geopolitical Conflicts on the 3D Printing Drugs Market
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Acceleration of Personalized Medicine Through Advanced Drug Delivery
- Improved Efficiency, Scalability, and Speed in Drug Manufacturing
- Transition Toward Decentralized and Point-of-Care Drug Manufacturing
- Market Restraints
- High Initial Investment and Limited Economic Scalability
- Regulatory Challenges and Limited Commercial Approvals
- Market Opportunities
- Expansion of Multi-Technology Platforms for Advanced Drug Delivery Systems
- Development of Complex and High-Value Drug Formulations
Chapter 4 Emerging Technologies
- Emerging Technologies
- AI-Integrated and IoT-Enabled 3D Printing of Drugs
- 4D Printing (Time-Dependent and Stimuli-Responsive Drug Delivery)
- Multi-Material and Multi-Drug Printing (Polypill Technology)
- Bioprinting and Tissue-Integrated Drug Delivery
Chapter 5 Market Segment Analysis
- Segmentation Breakdown
- Global Market for 3D Printing Drugs by Dosage Form
- Key Takeaways
- Tablet
- Capsules
- Transdermal Patches
- Others
- Global Market for 3D Printing Drugs by Technology
- Key Takeaways
- Fused Deposition Modeling (FDM)
- Inkjet Printing
- Binder Jet Printing
- Semi-Solid Extrusion (SSE)
- Selective Laser Sintering (SLS)
- Stereolithography (SLA)
- Others
- Global Market for 3D Printing Drugs by Application
- Key Takeaways
- Neurological Disorders
- Cardiovascular Disorders
- Oncology
- Others
- Geographic Breakdown
- Global Market for 3D Printing Drugs by Region
- Key Takeaways
- North America
- Europe
- Asia-Pacific
- South America
- Middle East and Africa
Chapter 6 Competitive Intelligence
- Key Takeaways
- Competitive Landscape
- Key Developments and Strategies
List of Tables
Summary Table: Global Market for 3D Printing Drugs, by Region, Through 2031
Table 1: List of FDA-Approved and IND-Approved 3D-Printed Pharmaceutical Products and Devices
Table 2: Types of 3D Printing Techniques Utilized in Product Development
Table 3: Global Market for 3D Printing Drugs, by Dosage Form, Through 2031
Table 4: Global 3D Printing Drugs Market for Tablets, by Region, Through 2031
Table 5: Global 3D Printing Drugs Market for Capsules, by Region, Through 2031
Table 6: Global 3D Printing Drugs Market for Transdermal Patches, by Region, Through 2031
Table 7: Global 3D Printing Drugs Market for Other Forms, by Region, Through 2031
Table 8: Global Market for 3D Printing Drugs, by Technology, Through 2031
Table 9: Global 3D Printing Drugs Market for Fused Deposition Modeling, by Region, Through 2031($ Thousands)
Table 10: Global 3D Printing Drugs Market for Inkjet Printing, by Region, Through 2031
Table 11: Global 3D Printing Drugs Market for Binder Jet Printing, by Region, Through 2031
Table 12: Global 3D Printing Drugs Market for Semi-Solid Extrusion, by Region, Through 2031($ Thousands)
Table 13: Global 3D Printing Drugs Market for Selective Laser Sintering, by Region, Through 2031($ Thousands)
Table 14: Global 3D Printing Drugs Market for Stereolithography, by Region, Through 2031($ Thousands)
Table 15: Global 3D Printing Drugs Market for Other Technologies, by Region, Through 2031
Table 16: Global Market for 3D Printing Drugs, by Application, Through 2031
Table 17: 3D-Printed Devices/MicroDevices and Their Applications in Neurological Sciences
Table 18: Global 3D Printing Drugs Market for Neurological Disorders, by Region, Through 2031
Table 19: Global 3D Printing Drugs Market for Cardiovascular Disorders, by Region, Through 2031
Table 20: Global 3D Printing Drugs Market for Oncology, by Region, Through 2031
Table 21: Global 3D Printing Drugs Market for Other Applications, by Region, Through 2031
Table 22: Global Market for 3D Printing Drugs, by Region, Through 2031
Table 23: North American Market for 3D Printing Drugs, by Dosage Form, Through 2031
Table 24: North American Market for 3D Printing Drugs, by Technology, Through 2031
Table 25: North American Market for 3D Printing Drugs, by Application, Through 2031
Table 26: European Market for 3D Printing Drugs, by Dosage Form, Through 2031
Table 27: European Market for 3D Printing Drugs, by Technology, Through 2031
Table 28: European Market for 3D Printing Drugs, by Application, Through 2031
Table 29: Asia-Pacific Market for 3D Printing Drugs, by Dosage Form, Through 2031
Table 30: Asia-Pacific Market for 3D Printing Drugs, by Technology, Through 2031
Table 31: Asia-Pacific Market for 3D Printing Drugs, by Application, Through 2031
Table 32: South American Market for 3D Printing Drugs, by Dosage Form, Through 2031
Table 33: South American Market for 3D Printing Drugs, by Technology, Through 2031
Table 34: South American Market for 3D Printing Drugs, by Application, Through 2031
Table 35: MEA Market for 3D Printing Drugs, by Dosage Form, Through 2031
Table 36: MEA Market for 3D Printing Drugs, by Technology, Through 2031
Table 37: MEA Market for 3D Printing Drugs, by Application, Through 2031
Table 38: Leading Provider of 3D Printing Drugs Market, 2025
Table 39: 3D Printing Drugs Market: Recent Strategic Developments, 2024-2026
Table 40: Abbreviations Used in this Report
Table 41: Report Sources
Table 42: Aprecia Pharmaceuticals: Company Snapshot
Table 43: Aprecia Pharmaceuticals: Product Portfolio
Table 44: Aprecia Pharmaceuticals: News/Key Developments, 2024-2025
Table 45: AstraZeneca: Company Snapshot
Table 46: AstraZeneca: Financial Performance, FY 2024 and 2025
Table 47: AstraZeneca: Product Portfolio
Table 48: CurifyLabs: Company Snapshot
Table 49: CurifyLabs: Product Portfolio
Table 50: CurifyLabs: News/Key Developments 2023
Table 51: FABRX LTD: Company Snapshot
Table 52: FABRX LTD: Product Portfolio
Table 53: FABRX LTD: News/Key Developments, 2024-2026
Table 54: GSK plc: Company Snapshot
Table 55: GSK plc: Financial Performance, FY 2024 and 2025
Table 56: GSK plc: Product Portfolio
Table 57: Johnson & Johnson: Company Snapshot
Table 58: Johnson & Johnson: Financial Performance, FY 2024 and 2025
Table 59: Johnson & Johnson: Product Portfolio
Table 60: Johnson & Johnson: News/Key Developments, 2025
Table 61: Laxxon Medical: Company Snapshot
Table 62: Laxxon Medical: Product Portfolio
Table 63: Laxxon Medical: News/Key Developments 2024-2025
Table 64: Merck KGaA: Company Snapshot
Table 65: Merck KGaA: Financial Performance, FY 2024 and 2025
Table 66: Merck KGaA: Product Portfolio
Table 67: Merck KGaA: News/Key Developments, 2026
Table 68: Multiply Labs Inc.: Company Snapshot
Table 69: Multiply Labs Inc: Product Portfolio
Table 70: Multiply Labs, Inc.: News/Key Developments 2025-2026
Table 71: TRIASTEK: Company Snapshot
Table 72: TRIASTEK: Product Portfolio
Table 73: TRIASTEK: News/Key Developments, 2024-2026
Table 74: Few Emerging Startups/Market Disruptors
List of Figures
Summary Figure: Global Market Shares for 3D Printing Drugs, by Region, 2025
Figure 1: Market Dynamics of 3D Printing Drugs
Figure 2: Emerging Technologies in the 3D Printing Drugs Market
Figure 3: Global Market Shares for 3D Printing Drugs, by Dosage Form, 2025
Figure 4: Global Market Shares for 3D Printing Drugs, by Technology, 2025
Figure 5: Global Market Shares for 3D Printing Drugs, by Application, 2025
Figure 6: Global Market Shares for 3D Printing Drugs, by Region, 2025
Figure 7: ASTRAZENECA: Revenue Shares, by Business Unit, FY 2025
Figure 8: ASTRAZENECA: Revenue Shares, by Region, FY 2025
Figure 9: GSK plc: Revenue Shares, by Business Unit, FY 2025
Figure 10: GSK plc: Revenue Shares, by Country/Region, FY 2025
Figure 11: Johnson & Johnson: Revenue Shares, by Business Unit, FY 2025
Figure 12: Johnson & Johnson: Revenue Shares, by Country/Region, FY 2025
Figure 13: Merck KGaA: Revenue Shares, by Business Unit, FY 2025
Figure 14: Merck KGaA: Revenue Shares, by Region, FY 2025
